Project/Area Number |
24591186
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Wakayama Medical University (2013-2014) Shizuoka Cancer Center Research Institute (2012) |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KOH Yasuhiro 和歌山県立医科大学, 医学部, 講師 (80426519)
SERIZAWA Masakuni 静岡県立静岡がんセンター研究所, 新規薬剤開発・評価研究部, 研究員 (00569915)
|
Co-Investigator(Renkei-kenkyūsha) |
KONDO Haruhiko 杏林大学, 呼吸器・甲状腺外科, 教授 (60399590)
ENDO Masahiro 静岡県立静岡がんセンター, 画像診断科, 部長
NAKAJIMA Takashi 静岡県立静岡がんセンター, 病理診断科, 部長 (20124422)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 遺伝子異常 / バイオバンク / 分子標的治療 / 遺伝子変異 / 肺癌 |
Outline of Final Research Achievements |
In this project, we established a biobank system of specimens from patients with thoracic malignancies. We conducted tumor genotyping study using tissue samples obtained from the biobank to detect 23 hotspot mutations in 9 cancer-related genes. In adenocarcinoma, EGFR mutation was most frequently detected (35.0%) followed by KRAS mutation (8.5%) and ALK translocation (5.0%). On the other hand, in small-cell lung cancer and squamous cell lung cancer, mutation rate was much lower than that in adenocarcinoma, suggesting driver mutations are rarely detected in those histologic types. We also established genotyping platform utilizing next-generation sequencing technologies for more comprehensive mutational analysis.
|